This looks promising.
Invivyd’s VYD2311 is being developed as a prophylactic monoclonal antibody candidate for the prevention of COVID-19.
DECLARATION (clinical trial NCT07298434) topline data from 2400 subjects is expected in October 2026.
clinicaltrials.gov/study/NCT072...
clinicaltrials.gov
ClinicalTrials.gov